ArticleScientific reports2021
Adverse outcomes associated with the treatment of Toxoplasma infections.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 51 citations in OpenAlex.
- Discovery of novel anti-RSC advances · 2026Article
- Anticancer proteasome inhibitors are detrimental to the growth of Toxoplasma gondii in vitro.BMC research notes · 2026Article
- Lead Optimization of TgCDPK1 Inhibitors for the Treatment of Toxoplasmosis.Journal of medicinal chemistry · 2026Article
- Evolutionary remodeling of ubiquinone biosynthesis in Toxoplasma gondii reveals an essential bi-functional monooxygenase.Nature communications · 2026Article
- Protective Immunity Induced by DNA Vaccines Encoding TgGRA47 and TgGRA72 AgainstTransboundary and emerging diseases · 2026Article
- BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion.Frontiers in cellular and infection microbiology · 2026Article
- Influenza virus-like particles presentingNanomedicine (London, England) · 2025Article
- Evaluation of anti-Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Article
- In Vivo Safety and Efficacy of Thiosemicarbazones in Experimental Mice Infected withBiomedicines · 2025Article
- Catechin gallate triggers metabolomic and lipidomic alteration in Toxoplasma gondii.Parasites & vectors · 2025Article
- Versatile Imidazole Scaffold with Potent Activity against Multiple Apicomplexan Parasites.ACS infectious diseases · 2025Article
- In Vitro Inhibitory Activity of Corilagin and Punicalagin AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Treatment with BKI-1748 afterAntimicrobial agents and chemotherapy · 2025Article
- Novel Drug Targets for the Bradyzoite Form ofResearch and reports in tropical medicine · 2025Review
- Anti-Toxoplasma gondii effects of XYP1-derived peptides and regulatory mechanisms of XYP1.Parasites & vectors · 2024Article
- Comparative evaluation of silver nanoparticles and human platelet rich-plasma versus traditional therapy in the treatment of murine chronic toxoplasmosis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Anti-Food science & nutrition · 2024Article
- An Early Treatment With BKI-1748 Exhibits Full Protection Against Abortion and Congenital Infection in Sheep Experimentally Infected With Toxoplasma gondii.The Journal of infectious diseases · 2024Article
- Zinc Oxide and Magnesium-Doped Zinc Oxide Nanoparticles Ameliorate Murine Chronic Toxoplasmosis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Apigeninidin chloride disruptsFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse outcomes associated with the treatment of Toxoplasma gondii infections in patients with various health backgrounds have not been characterized. The aim of this study was to identify the adverse outcomes and adverse events associated with the current clinical treatments of Toxoplama gondii infections using real world data reported to the FDA adverse event reporting system (FAERS). Data submitted to FAERS between 2013 and 2019 was retrieved and analyzed. Reporting odds ratio of death was calculated for the drugs having ≥ 25 reports of adverse outcomes. The adverse event profiles for the same drugs were analyzed and the reporting odds ratio was calculated relative to all other drugs used in the treatment of Toxoplasma infections. There were 503 cases reporting the treatment of Toxoplasma infections in the FAERS database. Death (DE) was the adverse outcome in 102 reports, of which 23 (22.5%) anti-Toxoplasma drugs were listed as the primary suspect drug (PS). Clindamycin (2.04; 1.07-3.90) followed by pyrimethamine (1.53; 0.99-2.36) were the most likely to be associated with death. Adverse events analysis suggest that sulfonamides formulations may have a less favorable safety profile. Our study represents the first real-world analysis of adverse outcomes and events associated with the treatment of Toxoplasma infections. Our findings support the need to better understand the current first-line agents for Toxoplasma infections, in addition to underscoring the need to identify safer regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.